Has Barbara Lawson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $16,744 in general payments to Barbara Lawson, MD across 118 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Barbara Lawson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Barbara Lawson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Barbara Lawson, MD

Interventional Cardiology · Richmond, VANPI 1598930182

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (51.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Edwards Lifesciences at 53.2% of the total. Reporting peaked in 2021 at $6,597 and has fallen 73.1% since, to $1,772 in 2025.

$16,744in general payments, 2019–2025

Across 118 payments — averaging $141.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Edwards Lifesciences$9K
Corindus Inc.$2K
Abbott$1K
Shockwave Medical, Inc$1K
Abiomed$1K
Philips North America LLC$807
plus $1K from 5 others

What the payments were for

Consulting fees$5,25031%
Travel & lodging$2,81817%
Food & beverage$8,67552%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Edwards Lifesciences	37	$8,903
Corindus Inc.	8	$1,918
Abbott	16	$1,480
Shockwave Medical, Inc	13	$1,411
Abiomed	15	$1,115
Philips North America LLC	9	$807
Cardiovascular Systems Inc.	6	$429
Asahi Intecc USA, Inc.	3	$364
Medtronic(2 entities)	4	$227
Terumo Medical Corporation	4	$69
GE HealthCare	3	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CorPath GRX$1,796
Edwards SAPIEN 3 Transcatheter Heart Valve$1,113
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$916
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$673
Diamondback Coronary$586
Impella$499
ASAHI PTCA Guide Wire$364
Ultreon$291
EVOQUE$189
DRAGONFLY OPSTAR$154
(6585) Omniwire$149
SAPIEN 3 Ultra RESILIA$141
(6571) Eagle Eye$132
COREVALVE EVOLUT R$117
XIENCE SIERRA$109
(6342) Intrasight Integrated$106
Xience Sierra Coronary Stent System$101

How this compares

$16,744 in reported general payments places this provider in the 80th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia →

Medicare billing

Part B allowed, 2024

$153,852

Medicare patients

475

Services billed

981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	57	$67,145
XareltoRivaroxaban	26	$33,930
EntrestoSacubitril/Valsartan	13	$26,186
JardianceEmpagliflozin	25	$18,449
Repatha SureclickEvolocumab	15	$8,025
Metoprolol Succinate	180	$2,103
Rosuvastatin Calcium	137	$1,858
Atorvastatin Calcium	204	$1,562
Carvedilol	117	$1,278
Pravastatin Sodium	37	$1,009
Torsemide	17	$926
Isosorbide Mononitrate ErIsosorbide Mononitrate	46	$853
Ezetimibe	59	$845
Amlodipine Besylate	148	$816
Ranolazine ErRanolazine	13	$741

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Richmond

Gansevoort DunningtonRichmond$440K
Matthew ChungRichmond$75K
Ashwani KumarRichmond$35K
Brinder KandaRichmond$34K
James GarnettRichmond$19K
John PosenauRichmond$11K
Michael ArcareseRichmond$10K
Sam DowRichmond$10K
Deepak TalrejaVirginia Beach$1.5M
Rajiv TayalFredericksburg$984K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →